Nektar Therapeutics (NASDAQ:NKTR – Get Rating) – William Blair reduced their Q2 2023 earnings per share estimates for shares of Nektar Therapeutics in a note issued to investors on Wednesday, May 10th. William Blair analyst A. Hsieh now anticipates that the biopharmaceutical company will earn ($0.27) per share for the quarter, down from their prior […]
Analysts At H.C. Wainwright & Co. Set 12-Month Target Of $15 Per Share For ENLV Thanks To High Profile Collaboration Agreement, Multiple Ongoing Clinical Trials streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
NES-ZIONA, ISRAEL / ACCESSWIRE / April 14, 2023 / This month, H.C. Wainwright & Co. reiterated its buy rating for Enlivex Therapeutics Ltd. (NASDAQ:ENLV) with a 12-month price target of $15 per share,
SAN DIEGO (BUSINESS WIRE) Ambrx Biopharma, Inc., or Ambrx (NYSE: AMAM), a clinical stage biopharmaceutical company using its proprietary Engineered Precision Biologics (EPBs) platform to create antibody-drug conjugates (ADCs), has appointed Sandra Aung, Ph.D., as Executive Vice President, Head of Clinical Developm.